VALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA
Open Access
- 17 April 2026
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , 2883-2889
Abstract
Context: The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world setting. Design: Retrospective observational study Setting: Tertiary care center Patients: Data from 670 PTC patients with complete histopathological and final disease outcome were included. Main Outcome measures: We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction. Results: The reclassification according to the 2025 ATA risk stratification showed that the proportion of “low-risk” PTC decreased by 22.2%, while “intermediate-risk” and “high-risk” PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the two stratification systems revealed that structural disease persistence in the 2025 “low-risk” and “high-risk” classes was comparable. The 2025 “intermediate-high-risk” class was similar to the former “intermediate-risk” class, whereas the “low-intermediate-risk” class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 “low-risk” class (p = 0.003), but lower than that of the 2015 “intermediate-risk” class (p = 0.012). Conclusions: In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined “low-intermediate-risk” class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior “low-risk” and “intermediate-risk” classes, highlighting the need for dedicated prospective studies to address proper management of this newly-defined group of patients.Keywords
Funding Information
- Ministero della Salute
This publication has 14 references indexed in Scilit:
- Summary and update on the management of differentiated thyroid cancer in 2023Annales d'Endocrinologie, 2024
- Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta‐analysisLaryngoscope Investigative Otolaryngology, 2022
- Les stratégies de désescalade pour les cancers différenciés de la thyroïdeBulletin du Cancer, 2021
- Association of Multifocality With Prognosis of Papillary Thyroid CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2021
- Thyroid Cancer Clinical Guidelines and the De-escalation of CareJAMA Otolaryngology–Head & Neck Surgery, 2020
- Active surveillance for patients with very low‐risk thyroid cancerLaryngoscope Investigative Otolaryngology, 2020
- Thyroid cancer surgery guidelines in an era of de-escalationEuropean Journal of Surgical Oncology, 2018
- Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinomaJournal of Surgical Oncology, 2017
- Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancerTumor Biology, 2016
- Prognostic impact of extra‐nodal extension in thyroid cancer: A meta‐analysisJournal of Surgical Oncology, 2015